EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Piperine improves levodopa availability in the 6‐OHDA ‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase

Xiaolu Hu, Lan Yu, Yatong Li, Xiaoxi Li, Yimeng Zhao, Lijuan Xiong, Jiaxuan Ai, Qijun Chen, Xing Wang, Xiaoqing Chen, Yinying Ba, Yaonan Wang und 1 weitere

CNS Neuroscience & Therapeutics · 2024-02 · 30 (2)

DOI: 10.1111/cns.14383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 01.08.2023. Verfasst von Xiaolu Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Lab of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome, Alkaloids, Piperidines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tyrosine decarboxylase (TDC) presented in the gut‐associated strain Enterococcus faecalis can convert levodopa (L‐dopa) into dopamine (DA), and its increased abundance would potentially minimize the availability and efficacy of L‐dopa. However, the known human decarboxylase inhibitors are ineffective in this bacteria‐mediated conversion. This study aims to investigate the inhibition of piperine (PIP) on L‐dopa bacterial metabolism and evaluates the synergistic effect of PIP combined with L‐dopa on Parkinson's disease (PD).

Methods

Metagenomics sequencing was adopted to determine the regulation of PIP on rat intestinal microbiota structure, especially on the relative abundance of E. faecalis . Then, the inhibitory effects of PIP on L‐dopa conversion and TDC expression of E. faecalis were tested in vitro. We examined the synergetic effect of the combination of L‐dopa and PIP on 6‐hydroxydopamine (6‐OHDA)‐lesioned rats and tested the regulations of L‐dopa bioavailability and brain DA level by pharmacokinetics study and MALDI‐MS imaging. Finally, we evaluated the microbiota‐dependent improvement effect of PIP on L‐dopa availability using pseudo‐germ‐free and E. faecalis ‐transplanted rats.

Results

We found that PIP combined with L‐dopa could better ameliorate the move disorders of 6‐OHDA‐lesioned rats by remarkably improving L‐dopa availability and brain DA level than L‐dopa alone, which was associated with the effect of PIP on suppressing the bacterial decarboxylation of L‐dopa via effectively downregulating the abnormal high abundances of E. faecalis and TDC in 6‐OHDA‐lesioned rats.

Conclusion

Oral administration of L‐dopa combined with PIP can improve L‐dopa availability and brain DA level in 6‐OHDA‐lesioned rats by suppressing intestinal bacterial TDC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseGastrointestinal MicrobiomeAlkaloidsPiperidinesBenzodioxolesPolyunsaturated AlkamidesHumansRatsAnimalsLevodopaOxidopamineTyrosine DecarboxylaseDopamineBacteriaAntiparkinson AgentsDisease Models, Animal

Stichwörter der Autor:innen

Enterococcus faecalisParkinson's diseaselevodopapiperinetyrosine decarboxylase

Substanzen

LevodopaOxidopaminepiperineTyrosine DecarboxylaseDopamineAntiparkinson AgentsAlkaloidsPiperidinesBenzodioxolesPolyunsaturated Alkamides

Autor:innen und Institutionen

  • Beijing Key Lab of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
  • Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, China.
  • School of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
  • Core facilities of modern pharmaceuticals, Capital Medical University, Beijing, China.

ORCID-Profile: Xia Wu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, X., Yu, L., Li, Y., Li, X., Zhao, Y., Xiong, L., Ai, J., Chen, Q., Wang, X., Chen, X., Ba, Y., Wang, Y., & Wu, X. (2024). Piperine improves levodopa availability in the 6‐OHDA ‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase. CNS Neuroscience & Therapeutics, 30(2). https://doi.org/10.1111/cns.14383

Vancouver

Hu X, Yu L, Li Y, Li X, Zhao Y, Xiong L, et al. Piperine improves levodopa availability in the 6‐OHDA ‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase. CNS Neuroscience & Therapeutics. 2024;30(2). doi:10.1111/cns.14383

BibTeX
@article{Hu2024,
  author = {Hu, Xiaolu and Yu, Lan and Li, Yatong and Li, Xiaoxi and Zhao, Yimeng and Xiong, Lijuan and Ai, Jiaxuan and Chen, Qijun and Wang, Xing and Chen, Xiaoqing and Ba, Yinying and Wang, Yaonan and Wu, Xia},
  title = {Piperine improves levodopa availability in the 6‐OHDA ‐lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  volume = {30},
  number = {2},
  doi = {10.1111/cns.14383}
}
Kostenlos starten →